

Cipla recognised as ESG champion at KPMG's ESG Conclave and Awards 2023

Mumbai, India; April 17th, 2023: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced that it has been awarded the **ESG Champion Award** in the 'Pharmaceutical & Healthcare sector' category by KPMG at their ESG Conclave and Awards, 2023, held in Mumbai.

The company emerged as a 'Champion' across all three pillars of Environmental, Social and Governance through its advanced initiatives. Cipla's reduction of its scope 1 & 2 GHG emissions, water usage, and waste generation from their operations in FY22 were outstanding facets under its environmental stewardship. Under social and community-building initiatives, Cipla ensured a supply of necessary drugs for non-communicable diseases, as outlined under WHO's essential medicines. Apart from its diversity & inclusion initiatives, Cipla also fared well given its strong measures on compliance, transparency and setting wide-ranging multi-stakeholder goals.

Driven by its purpose of 'Caring for Life', Cipla has always been dedicated towards enriching lives of the communities they work with. This recognition exemplifies the company's commitment towards environmental, social and governance stewardship. Cipla has been investing in greener technology and processes, creating social impact for communities, and serving markets to promote healthier people and a healthier planet.

Through this event, KPMG, a leading professional services network, aimed to increase the focus on sustainable action through strategic thought towards positive stakeholder impact and collectively establish a narrative for holistic ESG transformation in India. The conclave coincided with the firm's 30th year of being in the professional services business in India.

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 86 markets. Cipla is the 3rd largest in pharma in India (IQVIA MAT March '23), 3rd largest in the pharma private market in South Africa (IQVIA MAT March '23), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders.

For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Media Contacts:**Corporate Communications**

Heena Kanal

E-Mail: Heena.kanal@cipla.com**Investor Relations**

Naveen Bansal

E-Mail: Investor.Relations@cipla.com